A super-generic company that<br /><ul><li>brings drugs faster to market
creates new drug forms
saves 30% in drug production costs</li></ul>using PDG technology<br />
Market opportunity<br />Customers: pharmaceutical companies - originators and generics:<br />Formulation & Life cycle mana...
The problem with drugs ...<br />The Solution: <br />Pneumatic Dry Granulation (PDG)<br />PDG (Production)<br />PDG (Life c...
Low-cost alternative NOW available
Continuous production possible
Tablets have unwanted characteristics or don’t hold up
Long formulation times:  6-12 months
Upcoming SlideShare
Loading in …5
×

Atacama Labs @ MoneyTalks Espoo

1,151 views

Published on

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,151
On SlideShare
0
From Embeds
0
Number of Embeds
88
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Atacama Labs @ MoneyTalks Espoo

  1. 1. A super-generic company that<br /><ul><li>brings drugs faster to market
  2. 2. creates new drug forms
  3. 3. saves 30% in drug production costs</li></ul>using PDG technology<br />
  4. 4. Market opportunity<br />Customers: pharmaceutical companies - originators and generics:<br />Formulation & Life cycle management department<br />Production department<br />Under pressure: little new products, generic competition and cost pressure by health authorities<br />Market: development and production of tablets ($48.4B, +5%)<br />Targeted market: new tablets ($1.2B)<br />Very big market – 300 new products every year<br />Competition: <br />contract manufacturers (i.e. Patheon, Catalent, Aenova)<br />Production system providers (i.e. Alexanderwerk, Hosakawa, Fitzpatrick)<br />PDG Technology is unique (no base inventions since 20 years)<br />It solves development problems, speed-to-market issues and is cost effective<br />Market share target:<br />5% in 2015<br />Market share is only limited by development speed of capacity (investment)<br />
  5. 5. The problem with drugs ...<br />The Solution: <br />Pneumatic Dry Granulation (PDG)<br />PDG (Production)<br />PDG (Life cycle)<br />Life cycle mgmt.<br />(Gx) Production<br />Early development<br />PDG (Development)<br /><ul><li>Cost savings: 20-40% (=$7.5M)
  6. 6. Low-cost alternative NOW available
  7. 7. Continuous production possible
  8. 8. Tablets have unwanted characteristics or don’t hold up
  9. 9. Long formulation times: 6-12 months
  10. 10. Failure in scale-up (from lab to production)
  11. 11. Drug combinations possible
  12. 12. Fast dissolution (e.g. 15min.)
  13. 13. No stability issues
  14. 14. Increasing cost pressure in production (notably Gx); ~$25M prod. cost for $250M in sales
  15. 15. No low-cost production process alternative available
  16. 16. Continuous production not possible w/ wet granulation
  17. 17. Tablets are strong and have specified characteristics
  18. 18. Very short formulation time: 4-6 weeks
  19. 19. Same system for development and production
  20. 20. Drug combinations not possible
  21. 21. Onset of drug effect too slow (i.e. 30 min.)
  22. 22. Stability problems</li></ul>or<br />IP: 9 patents pending (all major countries), UK granted, US: Q4 2011<br />
  23. 23. The Benefit For Clients<br />Early development<br />Lifecycle management<br />Production<br /><ul><li>Time saved: 5-12 months
  24. 24. Costs saved: $0.5-1M/product
  25. 25. Higher reliability of development success
  26. 26. 30-40% lower production cost
  27. 27. Time saved: 5-12 months
  28. 28. Costs saved: $0.2-0.5M/product
  29. 29. Patent expiration solution
  30. 30. High market acceptance with convenient small tablet
  31. 31. Sales level maintained
  32. 32. 20-30% lower production cost
  33. 33. PDG solution works
  34. 34. Production cost saved: $5-7M*/product
  35. 35. No registration dossier changes needed (new product with new registration)</li></ul>*= average Gx product sales: $150M, today’s production costs: $22M (15% of sales), 25% saved: $5.6M<br />
  36. 36. Business Model<br />Clients:<br />Top 200 pharmaceutical originator companies (i.e. Pfizer, Glaxo, Novartis)<br />Top 30 pharmaceutical generic companies (i.e. Teva, Sandoz, Mylan)<br />Sales model (per product):<br />Contract development for fixed fee: $100-500K<br />Contract production / bulk tablet sales: $10-50M<br />Royalties on production of own patented products: 3-4% on sales<br />Earning model (per product):<br />Contract development for fixed fee: 25% = $25-125K<br />Contract production: split of savings = $1-6M<br />Royalties on production of own patented products: $1-2M<br />Licensing of technology (per system):<br />Development system (for lab): $1M<br />Licensing down-payment: $0.5M<br />Licensing earnings (per system):<br />Development system (for lab): 20% = $0.2M<br />Licensing earning: $0.5M<br />Customers today: <br /><ul><li>trials for 3 companies done, contract negotiations under way
  37. 37. Trials for 4 companies in preparation
  38. 38. 11 clients interested (after first presentations)
  39. 39. BD: Top 10 CMO partner, 2 distribution partners in US and Asia</li></li></ul><li>Company Roadmap<br />Own products (patents)<br />Product contracts<br />Distribution in Asia<br />Service launch fds<br />Own lab / prod. site<br />2010<br />2011-2012<br />2013<br />2014-2015<br />Milestones:<br /><ul><li>Develop V.3 PDG productionsystem
  40. 40. Develop2 internalproducts
  41. 41. File 2 formulationpatents
  42. 42. 6 clienttrials
  43. 43. 6contracts</li></ul>Milestones:<br /><ul><li>Develop 2 internalproducts
  44. 44. File 2 formulationpatents
  45. 45. Set-upnew lab & productionsite
  46. 46. 6 clienttrials
  47. 47. 6contracts</li></ul>Milestones:<br /><ul><li>V.2 PDG productionsystemcompleted
  48. 48. System installation / testing
  49. 49. 1 CMO partner
  50. 50. 1 distributionpartner
  51. 51. 3 internaltrials
  52. 52. 2 clienttrials</li></ul>Milestones:<br /><ul><li>Develop V.1 PDG lab system
  53. 53. 1 CMO partnerproviding high containmentenvironment
  54. 54. 2 distributionpartners
  55. 55. 2 internaltrials
  56. 56. 6clienttrials
  57. 57. 6contracts</li></li></ul><li>7<br />5 year P&L<br />7<br />
  58. 58. Management Team<br />Steffen Mittwich - CEO<br />20 yrs of pharmaceutical experience (Pfizer, Novartis, Sanofi-Aventis)<br />Launched Winthrop Generics (start-up) as CEO in Switzerland, grew from $0 to $6M in 2 yrs<br />Group Product Manager at Pfizer – brought Alzheimer’s product to market, grew from $0 to $75M in 3 yrs; responsible for $210M total in revenue from 1998 to 2001<br />Dr. Rob Lammens - CTO<br />30 yrs of pharmaceutical development and production experience at Bayer; expert in oral solid dosage forms and dry granulation / roller compaction<br />Improved scale-up from lab to production by creating a new system to determine process upgrade parameters saving approx. $1.3M development cost / product = $20M savings (15 products)<br />Developed leading roller compactor generation as consultant for Gerteis Maschinen Prozessengineering AG<br />Jari Ovaskainen– Main investor & chairman of the board<br />Founded Iobox in 1999, sold for $250M in 2000<br />
  59. 59. 9<br />Investment opportunity<br /><ul><li>The technology risk is eliminated and client interest is confirmed via trials
  60. 60. First contracts estimated for Q3-2011
  61. 61. A multitude of further client projects are available and achievable (production capacity for a further 8-10 projects)
  62. 62. Atacama seeks bridge funding of 2.85 m€ to secure initial deals (via test developments), broaden platform (high containment) and to cover operational costs
  63. 63. Break-even forecast: 2012</li></ul>www.atacamalabs.com<br />

×